169 related articles for article (PubMed ID: 26007739)
1. A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.
Lee SW; Hosokawa K; Kim S; Jeong OC; Lilja H; Laurell T; Maeda M
Sensors (Basel); 2015 May; 15(5):11972-87. PubMed ID: 26007739
[TBL] [Abstract][Full Text] [Related]
2. Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibody.
Lee S; Kim S; Malm J; Jeong OC; Lilja H; Laurell T
Anal Chim Acta; 2013 Sep; 796():108-14. PubMed ID: 24016590
[TBL] [Abstract][Full Text] [Related]
3. Macro-/nanoporous silicon as a support for high-performance protein microarrays.
Ressine A; Ekström S; Marko-Varga G; Laurell T
Anal Chem; 2003 Dec; 75(24):6968-74. PubMed ID: 14670060
[TBL] [Abstract][Full Text] [Related]
4. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
5. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
6. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
Väisänen V; Peltola MT; Lilja H; Nurmi M; Pettersson K
Anal Chem; 2006 Nov; 78(22):7809-15. PubMed ID: 17105175
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer.
Young CY; Seay T; Hogen K; Charlesworth MC; Roche PC; Klee GG; Tindall DJ
Prostate Suppl; 1996; 7():17-24. PubMed ID: 8950360
[TBL] [Abstract][Full Text] [Related]
8. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
Fisher TL; Nocera M; Willis RA; Turner MJ; Abdul Alim CS; Brown DM; Bourne PA; di Sant'Agnese PA; Messing EM; Lord EM; Frelinger JG
Prostate; 2002 May; 51(3):153-65. PubMed ID: 11967950
[TBL] [Abstract][Full Text] [Related]
9. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
10. Development of a dual monoclonal antibody immunoassay for total human kallikrein 2.
Finlay JA; Day JR; Evans CL; Carlson R; Kuus-Reichel K; Millar LS; Mikolajczyk SD; Goodmanson M; Klee GG; Rittenhouse HG
Clin Chem; 2001; 47(7):1218-24. PubMed ID: 11427452
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
[TBL] [Abstract][Full Text] [Related]
12. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D.
Hsieh ML; Charlesworth MC; Goodmanson M; Zhang S; Seay T; Klee GG; Tindall DJ; Young CY
Cancer Res; 1997 Jul; 57(13):2651-6. PubMed ID: 9205072
[TBL] [Abstract][Full Text] [Related]
13. Free and total human glandular kallikrein 2 in patients with prostate cancer.
Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
[TBL] [Abstract][Full Text] [Related]
14. Porous silicon surfaces: a candidate substrate for reverse protein arrays in cancer biomarker detection.
Ressine A; Corin I; Järås K; Guanti G; Simone C; Marko-Varga G; Laurell T
Electrophoresis; 2007 Dec; 28(23):4407-15. PubMed ID: 18041036
[TBL] [Abstract][Full Text] [Related]
15. Identification of human glandular kallikrein hK2 from LNCaP cells.
Grauer LS; Charlesworth MC; Saedi MS; Finlay JA; Liu RS; Kuus-Reichel K; Young CY; Tindall DJ
J Androl; 1996; 17(4):353-9. PubMed ID: 8889697
[TBL] [Abstract][Full Text] [Related]
16. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
17. Reverse-phase versus sandwich antibody microarray, technical comparison from a clinical perspective.
Järås K; Ressine A; Nilsson E; Malm J; Marko-Varga G; Lilja H; Laurell T
Anal Chem; 2007 Aug; 79(15):5817-25. PubMed ID: 17605470
[TBL] [Abstract][Full Text] [Related]
18. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
19. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
[TBL] [Abstract][Full Text] [Related]
20. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
Shariat SF; Kattan MW; Erdamar S; Nguyen C; Scardino PT; Spencer DM; Wheeler TM; Slawin KM
J Clin Oncol; 2003 Apr; 21(7):1223-31. PubMed ID: 12663708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
